Tiago Fauth analyst CREDIT SUISSE

Currently, out of the existing stock ratings of Tiago Fauth - 35 which are a Hold (26.72%), 90 which are a Buy (68.7%), 6 which are a Sell (4.58%)

Tiago Fauth

Work Performance Price Targets & Ratings Chart

Analyst Tiago Fauth works at CREDIT SUISSE and is covering the Healthcare sector with 241 price targets and ratings displayed on 26 stocks.

Tiago Fauth's average stock forecast success ratio is 48.24% with an average time for price targets to be met of 100.62 days.

Most recent stock forecast was given on VTYX, at 11-Aug-2023.

Wall Street Analyst Tiago Fauth

Analyst best performing recommendations are on HGEN (HUMANIGEN).
The best stock recommendation documented was for HGEN (HUMANIGEN) at 7/13/2022. The price target of $0.5 was fulfilled within 2 days with a profit of $0.11 (18.03%) receiving and performance score of 90.16.

Average potential price target upside

ABCL AbCellera Biologics APLS Apellis Pharmaceuticals ASND Ascendis Pharma A/S BCAB IFRX InflaRx N.V IMVT Immunovant KURA Kura Oncology ME 23andMe Holding Co UTHR United Therapeutics ALXO ALX Oncology Holdings ABSI AMGN Amgen ARGX argenx SE ARNA Arena Pharmaceuticals BMRN BioMarin Pharmaceutical HGEN Humanigen ICPT Intercept Pharmaceuticals RARE Ultragenyx Pharmaceutical RXDX SPRB Spruce Biosciences EDIT Editas Medicine VTYX FMTX GLTO ISEE PYXS

Analyst name


Current price target

Potential distance

Previous price target


Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score



$19.68 (455.56%)


4 months 2 days ago

0/2 (0%)

$18.78 (242.91%)



$27.4 (595.65%)


9 months 14 days ago

0/2 (0%)

$26.28 (203.09%)



$16.36 (352.59%)


10 months 16 days ago

0/3 (0%)

$11.23 (78.07%)



$13.36 (287.93%)

11 months ago

0/2 (0%)

$13.41 (78.97%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Tiago Fauth is most bullish on?

Potential upside of $53.99 has been obtained for RARE (ULTRAGENYX PHARMACEUTICAL)

Which stock is Tiago Fauth is most reserved on?

Potential downside of -$16.04 has been obtained for ASND (ASCENDIS PHARMA A/S)

What Year was the first public recommendation made by Tiago Fauth?

On 2017

To continue looking at which analysts cover the stock please register to the basic or advanced membership

How to use the chart